NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.240
+0.010 (0.81%)
Nov 5, 2024, 3:30 PM EST - Market open

NeuroSense Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Selling, General & Admin
4.84.784.971.590.390.34
Research & Development
6.927.275.591.392.50.9
Operating Expenses
11.7112.0510.552.992.891.24
Operating Income
-11.71-12.05-10.55-2.99-2.89-1.24
Interest & Investment Income
0.180.180.09---
Currency Exchange Gain (Loss)
0.020.02-0.02-0.030.060.02
Other Non Operating Income (Expenses)
1.741.74-0.01-0.2-0-0.01
Pretax Income
-9.8-10.11-10.49-3.22-2.83-1.22
Net Income
-9.8-10.11-10.49-3.22-2.83-1.22
Net Income to Common
-9.8-10.11-10.49-3.22-2.83-1.22
Shares Outstanding (Basic)
161412665
Shares Outstanding (Diluted)
161412665
Shares Change (YoY)
36.48%18.56%84.27%13.12%19.10%-
EPS (Basic)
-0.61-0.74-0.91-0.52-0.51-0.26
EPS (Diluted)
-0.61-0.74-0.91-0.52-0.51-0.26
Free Cash Flow
-10.21-8.38-7.69-1.56-0.7-0.59
Free Cash Flow Per Share
-0.63-0.61-0.67-0.25-0.13-0.13
EBITDA
-11.69-12.03-10.54-2.98-2.89-
D&A For EBITDA
0.020.020.0100-
EBIT
-11.71-12.05-10.55-2.99-2.89-1.24
Source: S&P Capital IQ. Standard template. Financial Sources.